https://www.news-medical.net/news/20230215/Neoadjuvant-nivolumab-treatment-improves-survival-rates-in-NSCLC-patients.aspx
Patients with resectable non-small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.
Create an account or login to join the discussion